Turku, Finland – November 1st, 2024 – DelsiTech Oy, a rapidly expanding drug delivery technology and development company headquartered in Turku, Finland, has appointed Carl-Åke Carlsson as its new Chief Executive Officer. This appointment marks a significant step in strengthening DelsiTech’s leadership team as it advances its proprietary technology and accelerates growth in the drug development sector.
DelsiTech, known for its innovative DelsiTech™ Silica Matrix drug delivery platform, will leverage Carl-Åke’s extensive industry expertise to sharpen its focus on developing its proprietary pipeline, while continuing its collaborative work with third-party customers and licensors. DelsiTech will continue to invest in and develop its proprietary technology with the aim to becoming the leader in long-acting injectable and ophthalmic treatments.
Carl-Åke Carlsson brings over thirty years of invaluable experience in the pharmaceutical industry, covering areas from Generic APIs and Branded Drug Products to Business-to-Business collaborations and Direct Market involvement. Previously holding senior leadership roles at Alpharma Inc. and Xellia Pharmaceuticals, Carl-Åke is also advising OneSource and the group of related companies, along with serving on various boards of directors.
“I am thrilled to step into this role, leading DelsiTech, as we work toward a promising future,” said Carl-Åke Carlsson. “DelsiTech is uniquely positioned to become a transformative leader in developing long-acting injectable and ophthalmic drugs, addressing critical patient needs. I’m excited to contribute my experience in business scaling and development to propel DelsiTech into its next phase of growth.”
Örjan Anderson, Chairman of DelsiTech, commented on the appointment: “We are excited to welcome Carl-Åke to DelsiTech. His extensive pharmaceutical industry experience will be instrumental as we continue our journey toward becoming a fully realized, high-growth, and profitable drug development company. With his leadership, our team is well-equipped to advance our mission of improving patients’ lives through innovative treatments”.
The company and the board is thanking Lasse Leino, CEO of DelsiTech for the last 11 years, for his invaluable contributions in building DelsiTech from a small start-up in 2013 to a prospering company ready to fulfill its potential and to reach new heights in the years to come.
About DelsiTech:
Based in Turku, Finland, DelsiTech Ltd. is a leading technology specialist in biodegradable, silica-based controlled release for small molecule drugs, biologics, and vaccines. DelsiTech partners with a range of pharmaceutical and biotech companies to bring innovative drug products to market through its proprietary delivery technologies. For more information, visit www.delsitech.com.
About DelsiTech™ Silica Matrix:
The DelsiTech™ Silica Matrix platform is an advanced drug delivery technology designed for parenteral and localized administration, suitable for injectable and implant dosage forms, as well as ophthalmic drops. Based on a biocompatible silica (SiO2) matrix, the Silica Matrix allows the therapeutic agent to be embedded through a unique sol-gel process. The non-porous, biodegradable matrix enables precise control over the release rate of active substances, providing sustained delivery from days to over a year.